Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage

J Biomed Biotechnol. 2010:2010:805907. doi: 10.1155/2010/805907. Epub 2010 Jun 29.

Abstract

The aim of the study was to investigate the DNA polymorphic genotype in MMP-2 promoter gene as a potential candidate region for the development of the cutaneous T-cell lymphoma (CTCL) and/or its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls of similar age and sex distribution, without personal or family history of chronic skin diseases and without personal history of malignancy. The three selected polymorphisms in the promoter of MMP-2 gene (-1575G/A, -1306C/T, and -790T/G) were determined using the PCR-based methodology with RFLP. In our cohort, the associated GGCCTT MMP-2 promoter genotype was highly significantly more frequent in CTCL-Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP-2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in the early stages.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Lymphoma, T-Cell, Cutaneous / enzymology*
  • Lymphoma, T-Cell, Cutaneous / genetics*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Matrix Metalloproteinase 2 / genetics*
  • Middle Aged
  • Neoplasm Staging
  • Parapsoriasis / genetics
  • Promoter Regions, Genetic*
  • Skin Neoplasms / enzymology*
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • Matrix Metalloproteinase 2